Could Earlier Access to a Promising Drug Change the Outlook for Pancreatic Cancer?

FDA decision opens door to investigational therapy as experts weigh impact, urgency and unanswered questions

One study found that 65% of respondents were hesitant about clinical trial enrollment.

Busting the Top 4 Myths About Clinical Trials

Health educator from Moffitt’s ACT WONDER2S initiative addresses common misconceptions

Heather Curley enjoys some family time with her daughter, Palmer, and husband, Dennis. When Heather was diagnosed with leptomeningeal disease, her prognosis was only two to four months.

Dendritic Cell Trial Brings Hope for Young Mom With Leptomeningeal Disease

Given just weeks to live, Heather Curley had no time to waste

AI opens the door to personalized melanoma treatments

Inside the Breakthroughs That Changed Melanoma Care

Moffitt researchers helped drive decades of FDA approvals that transformed patient outcomes

graphic of KRAS G12C mutation in non-small cell lung cancer (NSCLC)

New KRAS-Targeted Drugs Show Early Signals in Advanced Lung Cancer

Investigational therapies show tumor shrinkage in patients after standard treatments stop working

image of woman in hospital bed taking a pill

New Oral Targeted Therapy Shows Benefit in Hard to Treat Cancers

Early phase trial results show signs of tumor response and disease control in patients with advanced melanoma, colon, ovarian, cervical and thymic cancers

Moffitt Continues Studying CAR T To Treat Ovarian Cancer

Targeting specific hormone receptor found on cancer cells may be key to success

Skates, Strength and Second Chances

Melissa Nicholas brings the fight on and off the ice

Cancer Patient Cycles Over 100 Miles While Undergoing Treatment

Jorge Manchola enrolled in a clinical trial for his lung cancer at Moffitt last year

Endeavor

Cambiar el idioma